Q32 Bio (QTTB) Liabilities and Shareholders Equity (2017 - 2026)

Q32 Bio's Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $63.7 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 19.47% year-over-year to $63.7 million; the TTM figure through Mar 2026 stood at $249.4 million (down 37.69% YoY), while the FY2025 annual figure was $61.8 million, down 33.09% from the prior year.
• Liabilities and Shareholders Equity was $63.7 million for Q1 2026 at Q32 Bio, up from $61.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $311.0 million in Q1 2022 to a low of $47.1 million in Q4 2023.
• Historically, Liabilities and Shareholders Equity has averaged $143.7 million across 5 years, with a median of $124.2 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity sank 79.4% in 2023, then surged 96.21% in 2024.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $228.5 million in 2022, then tumbled by 79.4% to $47.1 million in 2023, then surged by 96.21% to $92.3 million in 2024, then tumbled by 33.09% to $61.8 million in 2025, then climbed by 3.07% to $63.7 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $63.7 million (Q1 2026), $61.8 million (Q4 2025), and $57.8 million (Q3 2025), per Business Quant data.